Markets:

Overview

News

Currencies

International

Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

29.00 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

May 28, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

May 18, 2026

From Stoke Therapeutics

Via Business Wire

Stoke Therapeutics Q1 Earnings Call Highlights ↗

May 09, 2026

Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year...

Via MarketBeat

Topics Earnings

Stoke Therapeutics (NASDAQ:STOK) Beats Q1 2026 Estimates as Phase 3 Trial Nears Completion ↗

May 07, 2026

Via Chartmill

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

May 07, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates

April 30, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

April 16, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

April 08, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

April 07, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares ↗

March 27, 2026

This biotech innovator in genetic disease therapies reported a notable insider sale amid a year of dramatic share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss

March 26, 2026

The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which...

Via MarketMinute

Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally ↗

March 24, 2026

This RNA therapeutics innovator for rare diseases reported a notable insider sale amid a year of dramatic share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

March 17, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

March 04, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

March 04, 2026

From Biogen Inc.

Via GlobeNewswire

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.

Via The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗

February 22, 2026

This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.

Via The Motley Fool

Topics Regulatory Compliance

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

February 22, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗

February 22, 2026

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗

February 22, 2026

Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

February 18, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

February 11, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 04, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

January 16, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Top movers in Monday's pre-market session ↗

January 12, 2026

Via Chartmill

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

January 11, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

December 16, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? ↗

December 10, 2025

This biotech targeting rare genetic diseases reported a notable insider sale following a year of rapid share price gains.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.